Inhibition of lung tumor growth by targeting EGFR/VEGFR-Akt/NF-κB pathways with novel theanine derivatives

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8528-8543

  Zhang, Guoying ^a,b   Ye, Xinshan ^b   Ji, Dexin ^a   Zhang, Huarong ^a   Sun, Fujia ^a   Shang, Chunqing ^a   Zhang, Ying ^a,c   Wu, Erxi ^c   Wang, Fengfei ^c   Wu, Fei ^a   Tian, Huihui ^a   Liu, Xin ^a   Chen, Linlin ^a   Liu, Kun ^a   Wang, Yishan ^d   Liu, Hanchen ^d   Zhang, Wenhua ^d   Guan, Yukun ^a   Wang, Qinwen ^e   Zhao, Xiaohang ^f   Wan, Xiaochun ^g   more..

^a YANTAI UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c NORTH DAKOTA STATE UNIVERSITY   (United States)

^d BINZHOU MEDICAL UNIVERSITY   (China)

^e Beijing 307 Hospital   (China)

^f CANCER HOSPITAL   (China)

^g ANHUI AGRICULTURAL UNIVERSITY   (China)

Author keywords

EGFR VEGFR Akt NF B pathways; Growth and migration; Inhibition; Lung cancer; Theanine derivatives; Xenograft mouse models

Indexed keywords

AMINO ACID DERIVATIVE; CISPLATIN; CYTARABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ETHYL 6 FLUOROCOUMARIN 3 CARBOXYLYL LEVO THEANINE; ETHYL 6 NITROCOUMARIN 3 CARBOXYLYL LEVO THEANINE; ETHYL COUMARIN 3 CARBOXYLYL LEVO THEANINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHOTREXATE; METHYL COUMARIN 3 CARBOXYLYL LEVO THEANINE; PROTEIN KINASE B; RECOMBINANT ENDOSTATIN; THEANINE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VINCRISTINE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CELL CYCLE PROTEIN; EGFR PROTEIN, HUMAN; EGFR PROTEIN, MOUSE; GLUTAMIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; DRUG POTENTIATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; LEWIS CARCINOMA; LEWIS LUNG CANCER; LUNG CANCER; LUNG CANCER CELL LINE; LUNG FIBROBLAST; LUNG TUMOR; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; C57BL MOUSE; CANCER STEM CELL; CARCINOMA, LEWIS LUNG; CELL MOTION; CELL PROLIFERATION; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; K562 CELL LINE; LEUKEMIA; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PATHOLOGY; SPRAGUE DAWLEY RAT; SYNTHESIS; TIME; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, LEWIS LUNG; CELL CYCLE PROTEINS; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; FEMALE; GLUTAMATES; HUMANS; K562 CELLS; LEUKEMIA; LUNG NEOPLASMS; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; NF-KAPPA B; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907983217     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2336     Document Type: Article

References (31)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62:10-29.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90.
3. Ahmedin J, Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ. Cancer Statistics. 2009; C.A. Cancer J. Clin. 2009; 9(59):225-249.
4. Siegel R, Ward E, Brawley O and Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. C.A. Cancer J. Clin. 2011; 61: 212-236.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002; 346: 92-98.
6. Dowell J, Minna JD and Kirkpatrick P. Erlotinib hydrochloride. Nat. Rev. Drug Discov. 2005; 4: 13-14.
7. Pal SK and Pegram M. Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. Anticancer Drugs. 2005; 6: 483-494.
8. Sugiyama T and Sadzuka Y. Enhancing effects of green tea components on the antitumor activity of adriamycin against M5076 ovarian sarcoma. Cancer Lett. 1998; 133: 19-26.
9. Sugiyama T, Sadzuka Y, Nagasawa K, Ohnishi N, Yokoyama T and Sonobe T. Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin. Jpn. J. Cancer Res. 1999; 90: 775-780.
10. Zhang G, Miura Y and Yagasaki K. Inhibitory effects of theanine and sera from theanine-fed rats on receptor-mediated cancer cell beneath mesothelial-cell monolayers. Cytotechnology. 2001; 36: 195-200.
11. Zhang G, Miura Y and Yagasaki K. Effects of dietary powdered green tea and theanine on tumor growth and hyperlipidemia in hepatoma-bearing rats. Biosci. Biotechnol.Biochem. 2002; 66 (4): 711-716.
12. Oltvai ZN, Milliman CL and Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993; 74: 609-619.
13. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance inhematologic malignancies. Semin. Hematol. 1997; 34: S9-S19.
14. Morelli, MP, Cascone T, Troiani T, Tuccillo C, Bianco R, Normanno N, Romano M, Veneziani BM, Fontanini G, Eckhardt SG, De Pacido S, Tortora G and Ciardiello F. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. Cell Physiol. 2006; 208(2): 344-353.
15. Lee JH, Choi S, Lee Y, Lee HJ, Kim KH, Ahn KS, Bae H, Lee HJ, Lee EO, Ahn KS, Ryu SY, Lü J and Kim SH. Herbal compound farnesiferol C exerts antiangiogenic and antitumor activity and targets multiple aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) signaling cascades. Mol. Cancer Ther. 2010; 9 (2): 389-399.
16. Liu W. Xu J, Wang M, Wang Q, Bi Y and Han M. Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. Int. J. Oncol. 2011; 39(5): 1213-1220.
17. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin. Cancer Res. 2009; 15 (10):3484-3494.
18. Zhang YM, Dai BL, Zheng L, Zhan YZ, Zhang J, Smith WW, Wang XL, Chen YN and He LC. A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylation. Cell Death Dis. 2012; 3:e406.
19. Zhang G, Wang Y, Zhang Y, Wan X, Li J, Liu K, Wang F, Liu K, Liu Q, Yang C, Yu P, Huang Y, Wang S, Jiang P, Qu Z, Luan J, et al. Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy. Current Mol. Med. 2012; 12: 163-176.
20. Wang S, Liu Q, Zhang Y, Liu K, Yu P, Liu K, Luan J, Duan H, Lu Z, Wang F, Wu E, Yagasaki K and Zhang G. Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action. Mol. Cancer. 2009; 8:81.
21. West KA, Castillo SS and Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 2002; 5: 234-248.
22. Wang CY, Mayo MW and Baldwin Jr. AS. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 1996; 274: 784-787.
23. Yu P, Liu Q, Liu K, Yagasaki K, Wu E and Zhang G. Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling. Cytotechnology. 2009; 59 (3): 219-229.
24. Marsden VS, O'Connor L, O'Reilly LA, Silke J, Metcalf D, Ekert PG, Huang DC, Cecconi F, Kuida K, Tomaselli KJ, Roy S,Nicholson DW, Vaux DL, Bouillet P, Adams JM and Strasser A. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature. 2002; 419: 634-437.
25. Deshmukh MN, Burud R, Baldino C, Chan PM and Liu JA. A practical and environmentally friendly preparation of 3-crboxycoumarins. Synthetic Commun. 2003; 33: 3299-3303.
26. Ito Y, Kitagawa H, Hiramori T, Suzuki Y and Yamagata M. Research of Coumarin Derivatives for Medical Purpose. III. Sedative and Hypnotic Actions. Yakugaku Zasshi. 1951; 71: 686-692.(In Japanese).
27. Li DY, Gu C, Min J, Chu ZH and Ou QJ. Maturation induction of human peripheral blood mononuclear cell-derived dendritic cells. Exp. Ther. Med. 2012; 4(1): 131-134.
28. Hsieh MJ, Tsai TL, Hsieh YS, Wang CJ, Chiou HL.Dioscin-induced autophagy mitigates cell apoptosis through modulation of PI3K/Akt and ERK and JNK signaling pathways in human lung cancer cell lines. Arch Toxicol. 2013; 87(11):1927-1937.
29. Liu Q, Duan H, Luan J, Yagasaki K and Zhang G. Effects of theanine on growth of human lung cancer and leukemia cells as well as migration and invasion of human lung cancer cells. Cytotechnology. 2009; 59 (3): 211-217.
30. Jiang Y, Zhang Y, Luan J, Duan H, Yagasaki K and Zhang G. Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action. Cytotechnology. 2010; 62: 578-583.
31. Williamson EA, Damiani L, Leitao A, Hu C, Hathaway H, Oprea T, Sklar L, Shaheen M, Bauman J, Wang W, Nickoloff JA, Lee SH and Hromas R. Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapy.Cancer Res. 2012; 72(23): 6200-6208.